Anticancer potential of mebendazole against chronic myeloid leukemia: in silico and in vitro studies revealed new insights about the mechanism of action

Chronic myeloid leukemia (CML) is caused by constitutively active fusion protein BCR-ABL1, and targeting ABL1 is a promising therapy option. Imatinib, dasatinib, and nilotinib have all been shown to work effectively in clinical trials. ABL1 mutations, particularly the T315I gate-keeper mutation, cau...

Descripción completa

Detalles Bibliográficos
Autores principales: Daniel, Julio Paulino, Mesquita, Felipe Pantoja, Da Silva, Emerson Lucena, de Souza, Pedro Filho Noronha, Lima, Luina Benevides, de Oliveira, Lais Lacerda Brasil, de Moraes, Maria Elisabete Amaral, Moreira-Nunes, Caroline de Fátima Aquino, Burbano, Rommel Mario Rodríguez, Zanatta, Geancarlo, Montenegro, Raquel Carvalho
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452629/
https://www.ncbi.nlm.nih.gov/pubmed/36091760
http://dx.doi.org/10.3389/fphar.2022.952250

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9452629/
https://www.ncbi.nlm.nih.gov/pubmed/36091760
http://dx.doi.org/10.3389/fphar.2022.952250

Ejemplares similares